- Molecular NameRifaximin
- SynonymRifamixin; Rifamycin L 105; Rifamycin L 105SV; Rifaxidin; rifaximin; Rifaximin [USAN:INN]; Rifaximina [Spanish]; Rifaximine [French]; Rifaximinum [Latin]
- Weight785.891
- Drugbank_IDDB01220
- ACS_NO80621-81-4
- Show 3D model
- LogP (experiment)4.161
- LogP (predicted, AB/LogP v2.0)4.81
- pka6.77
- LogD (pH=7, predicted)2.06
- Solubility (experiment)Insoluble
- LogS (predicted, ACD/Labs)(ph=7)-2.55
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.02
- No.of HBond Donors5
- No.of HBond Acceptors14
- No.of Rotatable Bonds3
- TPSA198.9
- StatusFDA approved
- AdministrationN/A
- PharmacologyA semisynthetic, rifamycin-based non-systemic antibiotic, meaning that very little of the drug will pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It is used in the treatment of traveler's diarrhea and hepatic encephalopathy
- Absorption_valueN/A
- Absorption (description)Low absorption in both the fasting state and when administered within 30 minutes of a high-fat breakfast.
- Caco_2N/A
- Bioavailability0.4
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIn vitro drug interactions studies have shown that rifaximin, at concentrations ranging from 2 to 200 ng/mL, did not inhibit human hepatic cytochrome P450 isoenzymes: 1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1, and 3A4. In an in vitro hepa-tocyte induction model, rifaximin was shown to induce cytochrome P450 3A4 (CYP3A4), an isoenzyme which rifampin is known to induce.
- Half life6 h
- ExcretionFecal (97%)
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A